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Colorectal cancer (CRC) represents the third most common malignancy throughout the world. Little or no improvement in
survival has been effectively achieved in the last 50 years. Extensive epidemiological and genetic data are able to identify more
precisely definite risk-groups so screening and early diagnosis can be more frequently accomplished. CRC is best detected by
colonoscopy, which allows sampling for histologic diagnosis. Colonoscopy is the gold standard for detection of small and premalignant
lesions, although it is not cost-effective for screening average-risk population. Colonoscopic polypectomy and mucosal resection
constitute curative treatment for selective cases of invasive CRC. Similarly, alternative trans-colonoscopic treatment can be offered
for adequate palliation, thus avoiding surgery.
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Colorectal cancer (CRC) represents
the third most common malignancy
worldwide1 and the second leading
cause of cancer-related death in the
U.S., regardless of sex. In 1998, it is
estimated that 20 000 cases were newly
diagnosed, and 6000 Brazilians died of
the disease2. Five-year associated mor-
tality remains unchanged around 50%3;
advances in the operative technique
and adjuvant therapy produced a mod-
est impact on survival4.
In this paper, a brief review of as-
pects of etiology, epidemiology, genet-
ics, histology, and main determinants
of prognosis of CRC will be followed
by an in-depth evaluation of the role of
colonoscopy in the screening, diagno-
sis, treatment, and surveillance of pa-
tients with CRC.
ETIOLOGY AND
EPIDEMIOLOGY
The colorectum is the most fre-
quent site for primary cancers in the
human body. Adenocarcinomas repre-
sent almost all CRCs. There are several
etiologic determinants of CRC, since
multiple steps are involved in its occur-
rence. Several genetic mutations have
been detected, and exogenous factors
interact for the development of the ac-
quired ones.
Sporadic CRC, or CRC not associ-
ated with inheritance, occurs more
commonly after the age of 60 and has
the sigmoid colon or rectum as the pri-
mary site in up to 65% of cases.
Known factors related to CRC eti-
ology include:
• diet: High insoluble fiber intake
seems to protect against CRC5.
Saturated fat intake in an amount
greater than 20% of meal calories
result in elevated cancer risk. Some
studies suggest that calcium has
protecting effects6,7,8. Elevated re-
fined sugar intake may predispose
to adenomas9 .
• smoking: An increase in carcinoma
incidence after a tobacco exposure
period greater than 35 years has
been demonstrated10.
• radiotherapy: Pelvic irradiation is
associated with an elevated risk of
rectal cancer11,12.
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• inflammatory bowel disease: Pa-
tients with ulcerative pancolitis or
ulcerative colitis (UC) diagnosed at
a young age are more susceptible to
CRC13. Cumulative incidence of
low- and high-grade dysplasia can
reach 90% and 25% respectively
after 37 years. Biopsy findings of
low-grade dysplasia are associated
with a 10% cancer-risk; high-grade
dysplasia between 30% and 40%
and dysplasia associated-lesion or
mass is associated with a risk
greater than 50%. Von Herbay et
al14 found that invasive CRC is as-
sociated with high-grade dysplasia
in 100% of cases. CRCs in UC are
more usually infiltrative and exhibit
mucinous histology. Sulfasalazine
therapy seems to reduce the cancer
risk associated with UC. In patients
with Crohn’s disease, cancer risk is
hard to define. Nevertheless, long-
standing disease and a narrowed lu-
men at colonoscopy may call
endoscopists to attention.
• adenomas: Most CRCs arise from
preexisting adenomatous pol-
yps15,16. Geographic and topo-
graphic distribution of adenocarci-
nomas is similar to adenomas.
There is ethnic conformity. One-
third of resected cancer specimens
include adenomas in a 6-times el-
evated prevalence when compared
to control groups without cancer.
Residual adenoma foci can be usu-
ally identified in adenocarcinomas,
and the atypia degree of an ad-
enoma is directly related to its
size17. Nevertheless, the strongest
indirect evidence for the adenoma-
carcinoma sequence comes from
the National Polyp Study in the
U.S. In this study, a 6-year follow-
up of patients who underwent
colonoscopic polypectomy, when
all polyps found were excised,
there was a 76% to 90% decrease
in CRC incidence when compared
to 3 control groups matched for
age18. Cancer risk of an adenoma is
related to its size and to villous his-
tology 19,20.
• cancer de novo: There is little
doubt that CRC can arise from
colorectal mucosa without a pre-ex-
isting adenomatous lesion21, al-
though the clinical significance of
this assumption remains unknown.
Findings of early CRC, especially
in flat-depressed lesions, have been
described by several endoscopists,
especially in Japan22,23,24,25. Flat ad-
enomas26 appear as reddish plaque-
like areas that are raised slightly
above the surrounding mucosa,
with or without a central depression
that exhibit air induced deformation
(the shape of the lesion changes af-
ter gas aspiration during colonos-
copy). Histologically, they are tubu-
lar adenomas where the height of
the adenomatous component does
not exceed twice the height of the
surrounding normal mucosa. A
high incidence of atypia has been
consistently reported for flat ad-
enomas26, and there is a general as-
sumption not only in Japan27,28,29,30
that CRC can rapidly arise from
these diminutive lesions, which can
be missed in conventional
colonoscopy.
GENETIC FINDINGS AND
HEREDITARY CRC
CRC is a genetic disease. Accumu-
lation of hereditary or acquired genetic
changes results in the development of
adenocarcinoma cells in colorectal
mucosa that have a growth advantage
since they do not respond to the nor-
mal determinants of cell growth, differ-
entiation, and death, leading to dyspla-
sia and invasive cancer 31,32. Oncogenes
(K-ras), tumor-suppressor genes (APC,
DCC e p53), and DNA (deoxyribo-
nucleic acid) mismatch repair genes
(MSH2, MLH1, PMS1, PMS2 e
MSH6) represent the three classes of
altered genes involved in CRC carcino-
genesis.
It is estimated that in up to 15% of
cases, CRC results from an initial he-
reditary genetic defect. In these cases,
CRC is part of a syndrome and is
called hereditary non-polyposis
colorectal cancer (HNPCC). HNPCC
patients are unable to repair DNA rep-
lication errors, since a MMR gene mu-
tation is detected in these cases. In
these patients, CRC develops more rap-
idly (usually before age 50) in the
proximal colon. It is preceded by a few
or no polyps, is more frequently mul-
tiple, and can be associated with other
cancers, such as breast, endometrial,
ovarial, pancreas, stomach, and kid-
ney33.
In 1% of all cases, CRC is associ-
ated with hundreds or thousands of
large bowel adenomas, as well as
periampullar adenomas or carcinomas
and desmoid tumors, as a result of a
dominant hereditary pattern or genetic
mutation. This phenotype is known as
familial adenomatous polyposis (FAP).
FAP results from mutation or deletion
of the tumor suppresser gene APC
(adenomatous polyposis coli). In up to
20% of FAP cases, the genetic defect
is not inherited. In these patients, CRC
arises from neoplastic changes in one
or more of the colorectal adenomas in
virtually all cases up to 45 years of age
if the entire large bowel is not surgi-
cally removed.
HISTOLOGIC AND
MACROSCOPIC FINDINGS
Carcinoma in situ refers to the pres-
ence of malignant cells exclusively
above the muscularis mucosa layer. It
is also known as superficial carcinoma
or severe dysplasia. Intraepithelial car-
cinoma refers to malignant cells exclu-
sively inside the epithelium. They are
restricted to the crypts of Lieberkühn.
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Invasive colorectal cancer (malig-
nant cells invading through the muscu-
laris mucosa layer to the submucosal
layer) is observed in up to 9% of
colorectal polyps removed in
colonoscopy34,35.
More commonly, early CRC pre-
sents in three forms: (1) malignant ad-
enoma or polypoid carcinoma; (2) a
malignant focus in a sessile adenoma;
or (3) a small ulcerated cancer. How-
ever, according to several Japanese
endoscopists early CRC are more fre-
quently flat depressed diminutive le-
sions36-42.
The classification of Haggitt44 for
early CRC is familiar to most gastro-
enterologists, endoscopists, and
colorectal surgeons. A polyp is pedun-
culated when the length of the pedicle
is larger than its diameter45. In
Haggitt’s classification, we define 4
levels of invasion for pedunculated pol-
yps:
• Level 0 — carcinoma above the
level of muscularis mucosa (in
situ);
• Level 1 — submucosal invasion
limited to the head of the polyp;
• Level 2 — carcinoma invading the
level of the neck of the adenoma;
• Level 3 — carcinoma invading any
part of the stalk; and
• Level 4 — invasion of the submu-
cosal layer of the bowel wall at the
base of the polyp.
According to Haggitt’s classifica-
tion, all sessile polyps with invasive
CRC represent level-4 invasion. How-
ever, authors from Japan classified
sessile lesions into 3 levels46,47:
• sm1 — slight submucosal invasion;
• sm2 — intermediate between sm1
and sm3; and
• sm3 — invasion into the full thick-
ness of the submucosa and internal
surface of the muscularis propria.
For pedunculated polyps, Haggit’s
level 1 is comparable to sm1, levels 2
and 3 are comparable to sm2, except
when the invasion is deep down in the
contact with the muscularis propria, in
which case it becomes sm3.
When looking for atypia in diminu-
tive colorectal lesions, no large US
study has reproduced the high-grade
dysplasia or severe atypia rate reported
by the Japanese. The US National
Polyp Study in 1984 (seven centers)
examined 572 diminutive adenomas
and showed only 0.9% high-grade dys-
plasia48. Muto reports up to 13%26 and
Mitooka, 13.5%49. It seems that there
is a growing consensus about the need
for applying chromoscopy and magni-
fication in Western populations in a
prospective surveillance for flat lesions
that can be missed during conventional
colonoscopy.
Macroscopic appearance of early
CRC was established according to the
classification for early gastric cancer of
the Japanese Society for Gastrointesti-
nal Endoscopy50. Diminutive lesions
can be divided in three classes: el-
evated, flat, or depressed. Each of these
has some subdivisions to describe a
pedicle or a central depression. It
seems that since these microscopic fea-
tures may vary according to intensity
of light, air deformation, and amount
of contrast, there may be a significant
variability between endoscopists when
trying to classify these lesions.
When describing large or advanced
CRC, endoscopists may use Borrmann’s
morphologic classification for advanced
gastric cancer51. Accordingly, CRC can
present in four distinctive forms: poly-
poid, ulcerated-vegetant, ulcerated-infil-
trative, and diffuse-infiltrative.
The usual microscopic colorectal
adenocarcinoma pattern is tubular with
or without papillary areas, well or
moderately differentiated (50% to 87%
of CRCs 52). In up to 20% of cases, the
glandular shape is irregular or there is
no shape (poorly differentiated can-
cers). Most CRCs have well defined
expansive margins (not infiltrative).
Mucinous tumors may be observed in
up to 15% of cases, and they are de-
fined by the presence of mucin in a
volume of at least 50% of the whole
lesion. The mucin may be within the
cell (signet ring cells) or without. Mu-
cinous tumors are associated with
young males, villous adenoma, radio-
therapy, and inflammatory bowel dis-
ease53.
SCREENING
Screening is the search for cancer
and precancerous polyps (adenomas) in
asymptomatic persons. Physicians and
lay persons are becoming increasingly
aware that most CRCs and most deaths
are preventable through screening.
Colonoscopy with polypectomy
represents only one method to find and
remove premalignant lesions in the en-
tire large bowel. Although colonoscopy
follows and exceeds the principles of
screening (since polyps are removed),
there is no study in a randomized or
case control setting to demonstrate its
effectiveness in reducing mortality as-
sociated with CRC. Available evidence
that favor colonoscopy are: case con-
trol studies demonstrated a 60%–70%
reduction in CRC mortality in the dis-
tal colon from sigmoidoscopy and
polypectomy; a cohort of patients who
underwent colonoscopy and clearing of
adenomas experienced a 76%–90% re-
duction in CRC incidence compared to
reference populations; cross-sectional
studies of screening colonoscopy in
average-risk population demonstrate a
prevalence of adenomas more than
twice that detected on average by flex-
ible sigmoidoscopy; currently, near
40% of all CRCs in the US arise proxi-
mal to the splenic flexure54.
In spite of these advantages, the
need for bowel preparation, sedation,
and risks associated with the exam it-
self or polypectomy constitute the
main causes for the low population ad-
herence to screening programs includ-
ing colonoscopy. Nevertheless colonos-
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copy may be used as the preferred
screening strategy for the average-risk
population (persons age 50 and older
who have no risk factors for CRC other
than age). In this population, full
colonoscopic examination may be
done every 10 years as an alternative
to flexible sigmoidoscopy every 5
years plus annual fecal occult blood
testing54.
Colonoscopy remains the choice
screening method for those with high
and moderately increased risk for CRC
55
. It is estimated that these individuals
account for 20% to 30% of popula-
tion56:
• individuals with a family history
of CRC in a single first-degree
relative at age > 55 year. Start
colonoscopy at age 50 and repeat at
5- or 10-year intervals;
• individuals with a family history
of CRC in a single first-degree
relative at age < 55 year or in two
or more first-degree relatives at
any age. Start colonoscopy at age
40 or 10 years before the youngest
age that cancer was diagnosed. Re-
peat at 5 year intervals;
• personal history of  1 cm- or
larger polyp or multiple polyps of
any size. Repeat colonoscopy 1
year after polypectomy and at 5
year-intervals between negative ex-
ams;
• personal history of CRC — see
CRC surveillance.
ENDOSCOPIC DIAGNOSIS AND
STAGING
In contrast to CRC screening, there
is a need for diagnosis when symptoms
are observed. In the majority of these
cases, the endoscopist can expect find-
ings of advanced colorectal cancer.
When efficacy of endoscopy and
barium enema in the diagnosis of CRC
are compared with colonoscopy, a sig-
nificant bias can be expected due to the
expertise and medical specialty of the
authors. However, it seems reasonable
to conclude that colonoscopy would be
the most effective exam for the large
bowel and terminal ileum, since it per-
mits direct identification of the tumor,
histologic examination through biopsy,
diagnosis and removal of synchronic
polyps, and staging attempts through
endoscopic ultrasound (EUS) tech-
niques. Sporadic CRC is associated
with synchronous cancer in up to 4%57
and to synchronous adenomas in up to
25%58 of cases. Supplemental colonos-
copy may follow barium enema in up
to 40% of cases due to inadequate
preparation or reasonable doubt59.
Barium enema sensitivity for the diag-
nosis of CRC in patients with positive
fecal occult blood testing remains be-
tween 50% and 75%60. Nevertheless,
for double contrast barium enema,
there can be similarity between radio-
logic and endoscopic methods for the
diagnosis of CRC in asymptomatic in-
dividuals60. Although this may be true,
additional information regarding his-
tology, search for synchronous polyps,
and flat lesions through chromoscopy
and staging will be lacking with
barium enema alone.
Colonoscopy has limitations in the
diagnosis of CRC. A lower sensitivity
should be expected in conditions of
poor bowel preparation as seen in di-
verticular disease, for some locations in
the large bowel known as “blind” re-
gions (behind large bowel folds and in
segments where intubation was techni-
cally demanding) and in cases when
complete examination couldn’t be at-
tempted.
Carcinoma in situ is more com-
monly a histologic diagnosis of a poly-
poid lesion excised during colonoscopy.
Reports of lymph node metastasis for in
situ or intramucosal carcinomas are an-
ecdotal61. Therefore, for lesions with
clear histologic margins, complete re-
section by endoscopy remains a suffi-
cient curative treatment44,62,63.
 Symptomatic individuals usually
present with advanced lesions. Endo-
scopic findings may easily follow
Borrmann’s nomenclature. Advanced
lesions are usually greater than 2 cm,
indurated, present with irregular surface
and spontaneous ulcerations, and usu-
ally bleed after biopsy. There is little
mobility following manipulation with
the snare, and for those lesions eventu-
ally considered for total excision
through endoscopic mucosal resection,
little or no elevation may be observed
after submucosal injection of saline.
Advanced CRC represents a lesion with
detected invasion into the muscularis
propria. Oncologic colon resection is
recommended treatment for colon le-
sions. For advanced rectal lesions, sur-
gical treatment is indicated. This ap-
proach encompasses local resection,
anterior resection, or abdominoperineal
resection. For advanced rectal lesions,
pre- or postoperative adjuvant treatment
is recommended for cure.
The presence of early CRC remains
the challenge for diagnostic colonos-
copy. Since endoscopic resection may
be sufficient treatment in some situa-
tions, there is a need for precise endo-
scopic diagnosis of the level of invasion.
EUS, chromoscopy, and magnifying
colonoscopy (MC) are useful tools in
the diagnosis of CRC as well as for im-
mediate staging.
Chromoscopy
Using a conventional endoscope, the
surface of the colon appears smooth.
But when looking more closely, the
mucosa would actually appear granular
and be divided by innominate grooves
into “colon areas”. The granular appear-
ance of these colon areas is due to nu-
merous pits in the colonic mucosa,
which represent the crypts of
Lieberkühn (intestinal glands). These
minute pits are arranged regularly and
are round in shape. The diameter of
each pit is 40 to 50 µm. Two methods
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—chromoscopy and MC — are cur-
rently used to see the colon surface
more clearly and are being used to-
gether or separately.
Tissue staining can be accomplished
during colonoscopy by injection, spray-
ing with a catheter, ingestion of a cap-
sule, or enema64. Tissue stains may be
divided into three categories. The first
uses absorptive stains that identify spe-
cific cells or cell components. Methyl-
ene blue may identify colorectal neo-
plastic lesions since absence of staining
usually indicates neoplastic change. An-
other absorptive stain is cresyl violet,
which stains the margins of the pits on
the mucosal surface allowing a very
clear definition of the pit pattern. The
second category is reactive stains that
identify cellular products through color
change as a result of a pH shift. Congo
red changes from red to dark blue when
pH < 3and can be used to enhance vi-
sualization of diminutive colorectal le-
sions65. The third category is contrast
stains. Not absorbed by the epithelium,
they highlight tissue topography by
pooling in epithelial crevices and de-
pressions. Indigo carmine 0.4% to 4%
is the best example in this category.
Since chromoscopy highlights per-
ception of the epithelial surface, there
may be potential to enhance endoscopic
diagnosis of diminutive colorectal lesions
when stains are used in an orderly fash-
ion. Nevertheless, it has not yet been pos-
sible to reliably predict the histologic di-
agnosis using chromoscopy and
conventional endoscopy. George et al.64,
using contrast chromoscopy with 0.2%
indigo carmine dye and conventional
colonoscopy could correctly predict his-
tologic diagnosis in only 47% of 89 di-
minutive colorectal lesions (< 5mm).
Polypectomy may routinely follow diag-
nosis of all lesions through chromoscopy.
Magnifying colonoscopy (MC)
MC consists in the utilization of an
optical system assembled to a video-
colonoscope. This endoscope has the
ability to produce a magnified view (3X
to 170X) of the entire colorectal mu-
cosal surface. Magnification can be au-
tomatic or may follow manual activa-
tion.
The ability to predict the histology
of polyps on endoscopic examination
remains a fascinating challenge that
could reduce CRC screening and sur-
veillance costs. The final goal of MC is
in vivo histologic diagnosis through
magnified observation of pit patterns in
identified lesions. During MC, the ordi-
nary detection of a lesion is followed by
mucus washout with water jet and con-
trast or absorptive chromoscopy. Mag-
nified observation permits pit pattern
analysis in the lesion and subsequent
classification. After stereomicroscopic
observation of 1676 lesions, Kudo66 pro-
posed 5 categories in his pit pattern clas-
sification. According to his experience,
neoplastic lesions were adequately dif-
ferentiated from non-neoplastic ones.
Kudo states that correct pit pattern
evaluation only can be done at 100X
magnification at which adequate focus
is hard to obtain, so the procedure be-
comes technically difficult. Another in-
teresting property of MC is the ability
to define the degree of invasion of a
colorectal lesion. According to Kudo,
the fifth category of his classification
(V) would indicate massive invasion of
the submucosal layer. It seems reason-
able to admit that pit pattern analysis
correlates to the histologic diagnosis.
However, we understand that the sensi-
tivity of the qualitative diagnosis, as
well as the accuracy of diagnosis by MC
of submucosal invasion, remains to be
determined.
Virtual colonoscopy (VC)
Computed tomography (CT)
colography, or VC, generates high
resolution two- and three-dimensional
images of the entire colorectal struc-
ture. It represents an attractive alterna-
tive for diagnosis and screening for
CRC. VC involves data input from a
helical CT scanner, which is then pro-
cessed by advanced computer soft-
ware. The main related advantages are:
1. VC foregoes colon intubation and
results in no risk of colon perforation;
2. there is no need for sedation and bet-
ter acceptance may be accomplished;
3. full colon evaluation can be ex-
pected even for patients where conven-
tional colonoscopy cannot be at-
tempted; 4. VC provides the exact
location of diagnosed lesions. However
VC still demands full bowel prepara-
tion in order to enhance sensitivity and
specificity, since fecal residues may be
interpreted as elevated lesions. Experi-
mental evidence shows that irradiation
is less than half of the amount used
during barium enema. Initial reports
state that sensitivity and specificity are
100% for polyps > 1cm; for polyps >
0.5 cm, sensitivity was 100% and
specificity was 80%, and for polyps
<0.5 cm, sensitivity was 42%. Several
technical problems and diagnostic is-
sues must be addressed before VC is
incorporated into practice: 1. enhanc-
ing image resolution to detect diminu-
tive and flat lesions; 2. refining image
subtraction technology to minimize
misdiagnosis due to fecal residues; 3.
evaluating collapsed colon segments
even after pneumocolon; and 4. reduc-
ing costs mainly related to image
analysis67.
Endorectal (ERUS) and endoscopic
ultrasound (EUS)
Introduced by Dukes in 192868 for
rectal adenocarcinoma, pathologic
staging still remains the strongest pre-
dictor of survival for patients with
CRC53,69. CRC staging refers to the ex-
act knowledge of the degree of tumor
infiltration in the bowel wall, the extent
and location of lymph node involve-
ment and the presence of distant me-
tastasis.
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CRC does not lead to lymph node
metastasis if malignant cells are above
the muscularis mucosa 70. For early
CRCs, lymphatic spread can be ex-
pected in 4% of cases71 if the cancer is
well or moderately differentiated. For
CRCs invading through the muscularis
propria, lymph node metastasis are ex-
pected in up to 20%. When CRC
reaches pericolic or perirectal tissues
(complete invasion of the bowel wall),
lymph nodes metastasis are observed in
up to 58%72 of cases.
Rectal cancer staging can be ac-
complished with ERUS, since the tu-
mor is accessible by the probe. ERUS
may follow a distal washout enema and
foregoes sedation and x-rays. Accuracy
for diagnosis of depth of penetration in
the rectal wall reaches 93%73 and for
lymph node involvement is 84%74. It
has been demonstrated that preopera-
tive chemoradiation therapy induces
significant and sometimes complete tu-
mor regression. Therefore, post-
chemoradiation staging is necessary in
order to evaluate tumor response and
further treatment. However, the accu-
racy of ERUS for the diagnosis of pen-
etration depth after chemoradiation as
first line treatment for low rectal can-
cer is only 8.3%75.
The development of high-fre-
quency and small-size EUS probes has
stimulated endoscopists to use this im-
aging modality to produce a significant
improvement in the correct diagnosis
of suspected submucosal lesions or ex-
trinsic masses, as well as, most impor-
tantly, in ruling out invasive submu-
cosal layer invasion or advanced
cancers, since both findings preclude
any attempt of endoscopic therapy of
suspected benign or early malignant
colorectal lesions. The accuracy of
EUS for the diagnosis of invasive can-
cer is around 76%. For intramucosal
carcinomas, accuracy was 83%, for
early invasive cancers, 90%, but for
advanced cancer, 50%76. Overall accu-
racy for the diagnosis of bowel wall
depth of invasion using EUS is be-
tween 70% and 90%77,78.
ENDOSCOPIC TREATMENT OF
CRC
The malignant polyp
Complete endoscopic excision with
clear histiologic margins is sufficient
treatment for in situ and intramucosal
carcinomas. Incomplete resection leads
to invasive cancer. Contrast chromos-
copy enhances definition of resection
margins.
When considering curative endo-
scopic treatment of early CRC, it is
critical to recognize that oncologic
colectomy is the only method for dem-
onstrating and harvesting lymph node
involvement. When dealing with can-
cer, cure and survival remain central
objectives. Therefore, any attempts at
endoscopic treatment on a day-by-day
basis should be done considering re-
sults of surgical options available after
a multi-specialty (pathologist,
endoscopist, and surgeon) consensus.
For pedunculated polyps with inva-
sive cancer, the presence of malignant
cells invading the submucosa at the
polyp’s head (Haggitt’s level 1), neck
(level 2), or stalk (level 3) results in
overall low risk of lymph node involve-
ment44,63,79,80-82. Cranley83 showed in a
review of 17 experiences, including
589 pedunculated malignant polyps
(polyps with invasive cancer), that only
1% of the polyps with “good” histol-
ogy (good/moderate differentiation, 2
mm-clear margin at the stalk, and no
vascular invasion) resulted in cancer
diagnosis at laparotomy or led to recur-
rence. Nevertheless, pedunculated pol-
yps with invasive cancer at Haggit’s
level 4, as well as sessile polyps with
invasive cancer at the submucosal
layer, may exhibit lymph node involve-
ment in up to 10%71,84 of cases. Accord-
ing to Muto85, the risk of lymph node
involvement for early invasive sessile
cancers of the sm3 level of submucosal
invasion is between 27% and 69%. For
pedunculated polyps with neoplastic
involvement observed at the stalk, an
adverse outcome may be observed in
up to 13%86 of cases. Almost all of
these patients had poorly differentiated
cancers with lymphatic or blood ves-
sel invasion.
The precise definition of clear mar-
gins (2 to 3 mm between lesion mar-
gins and diathermy margins according
to Muto85) is a problem that remains to
be solved, and incomplete resection is
a well known cause for recurrence or
invasive cancer. Some authors believe
that a portion of the therapeutic failures
associated with sessile lesions come
from incomplete resections due to un-
derestimating the position of the mar-
gin of the lesion. Endoscopic tattooing
is unequivocally a wise routine deci-
sion in the management of larger
sessile lesions, since it allows histo-
logic processing and definitive diagno-
sis followed by a guided endoscopic,
laparoscopic, or either open salvage
procedure if necessary87,88.
When dealing with advanced CRC,
a representative tumor fragment must
be taken from central area of the lesion
since marginal specimens may be fre-
quently re-epithelized or exhibit pure
adenomatous component.
For pedunculated lesions, snare di-
athermy polypectomy remains ad-
equate treatment. For large stalks, use
of heater probe or 1:10 000 epineph-
rine injection may optimize resection
through avoidance of bleeding. For
sessile lesions 2.5 cm-size or less, en-
doscopic mucosal resection assisted
with saline submucosal injection is rec-
ommended. For larger lesions, piece-
meal or sequential resections are the
best alternatives.
Endoscopic findings that may an-
ticipate elevated risk of bowel perfora-
tion or raise the possibility of dealing
with an advanced cancer are: lesions
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larger than 40 mm; central depression
observed after chromoscopy, non-lift-
ing signal after submucosal saline in-
jection; diagnosis of pit patterns III and
V at MC, and, obviously, EUS diagno-
sis of massive invasion of the submu-
cosa.
Equal or greater care must be taken
when dealing with specimen conserva-
tion. Immediately before formalization,
sessile lesions must be fixed with pins,
pedunculated lesions must be longitu-
dinally sectioned, and the stalk must be
clearly identified with a pin.
Endoscopic palliative treatment for
obstructive CRC
Intestinal obstruction is a frequent
clinical presentation of left-sided tu-
mors. Radical treatment through an
oncological operation is the treatment
of choice when cure is attempted, and
palliative resections may de done
through laparoscopy or conventional
access with the aim of symptomatic re-
lief and prevention of obstruction.
When cure cannot be achieved, avoid-
ing a colostomy may optimize quality
of life. Colonoscopy may have a role
in these situations.
Laser (Nd:YAG) ablation was
proven to be safe and effective for
avoiding intestinal obstruction from
advanced colorectal lesions. In a 7-cen-
ter, 60-patient European experience89,
an 80% rate of response was observed,
and mortality associated with laser
therapy was 3.3%. Schulze and Lyng90
evaluated the Nd:YAG laser for endo-
scopic tumor ablation in 74 dissemi-
nated CRC patients. Symptomatic re-
lief was observed in 74%. There was
no mortality; however, the authors de-
tected 5 cases of perforation and 1 of
bleeding. The main advantages of la-
ser ablation include the possibility of
multiple sessions and no need for ana-
esthesia. Perforation is the primary
concern, and stenosis may occur lead-
ing to urgent colostomy. Laser ablation
may be used in the preoperative setting
for patients with partial or complete
intestinal obstruction91,92. Laser abla-
tion may reduce tumor size and alle-
viate obstruction so careful bowel prep
can be delivered. Laser-associated
costs remain uniformly elevated, and
financial burden remains main reason
for its limited availability in most cen-
ters.
Photodynamic therapy (PDT) is a
treatment modality in which limited
cell death and tissue necrosis result
from interaction between a photosen-
sitizing agent taken up by a neoplastic
tissue and a defined wave-length low-
power light93. There is no thermal ef-
fect, so perforation risk is decreased.
Target tissue cells exposed to the agent
(more commonly, a hematoporphyrin
derivative administered intravenously)
undergo selective death in the presence
of oxygen. The mucosal layer is more
affected as result of agent-affinity and
light penetration. Associated cutaneous
photosensitivity may be severe, persists
for up to 6 weeks, and represents the
main drawback, since severe burns
may occur from solar exposure.
Insertion of expandable metal
stents for non-surgical palliation in pa-
tients with symptomatic near-obstruc-
tive colonic tumors may be achieved
through a single endoscopic examina-
tion, as opposed to laser therapy in
which multiple sessions are required,
and thus representing an attractive al-
ternative. Rey et al.94 described their
experience with 12 patients with rec-
tosigmoid carcinoma. In this series,
there were no complications associated
with the prosthesis, although migration
occurred in 3 patients, necessitating
stent removal. Saida et al.95 published
results of a 15-patient series in which
stent insertion was undertaken prior to
bowel prep and elective resection for
obstructive CRC. There were 2 perfo-
rations and 1 migration. In the remain-
ing 13 patients, bowel prep was con-
sidered adequate during the operation.
Perforation, migration, pain, and tumor
overgrowth represent the main ob-
stacles for stent treatment, and results
of flexible metallic mesh prosthesis in-
sertion need further evaluation96.
SURVEILLANCE
Patients who undergo endoscopic
mucosal resection of an invasive carci-
noma may need endoscopic re-exami-
nation up to 6 months after resection,
although there is no available evidence
of benefit from this approach.
For patients with non-early CRC
who underwent radical surgery, there is
reasonable doubt about the role of sur-
veillance colonoscopy in the diagnosis
of potentially curative recurrences,
since most of them occur as an extrin-
sic growth. For 113 cases of recurrence
reviewed by Virgo et al.97, colonoscopy
could first demonstrate recurrence in
only 3 cases.
Although definitive evidence is still
lacking, there may be some survival
benefit associated with dedicated fol-
low-up, since colonoscopy combined
with clinical, laboratory, and image
evaluations, and more recently with the
aid of positron emission tomography,
remain the only way to diagnose resec-
table recurrences.
Major attention should be paid to
the need of at least one full colonos-
copic evaluation when the first diagno-
sis of CRC is done. For obstructing le-
sions, postoperative examination may
follow an interval not greater than 6
months. Virtual colonoscopy may have
a role in this setting. According to the
American Cancer Society, American
College of Gastroenterology, and
American Society of Colon and Rec-
tal Surgeons, further examinations are
recommended on a 3- to 5-year basis55.
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pos de risco, específicos para o CCR,
favorecendo a aplicação de protocolos
de rastreamento e possibilitando
maior diagnóstico precoce. O CCR é
melhor diagnosticado pelo exame
colonoscópico que possibilita diagnós-
tico histológico através da biópsia. Le-
sões pré-malignas e cânceres precoces
são diagnosticados preferencialmente
pela colonoscopia em nosso meio. No
entanto, significativa redução de custos
se faz necessária à sua aplicação no
rastreamento da população de risco
normal para CCR. A polipectomia e a
mucossectomia endoscópicas represen-
tam tratamento curativo para casos se-
lecionados de CCR invasivo. Da mes-
ma forma, adequada paliação pode ser
alcançada utilizando alguns recursos da
colonoscopia.
DESCRITORES: Rastreamento
do câncer colorretal. Diagnóstico do
câncer colorretal. Colonoscopia.
Pólipos colorretais. Lesões.
ARAUJO SEA et al. - Papel da
colonoscopia no câncer colorretal. Rev.
Hosp. Clín. Fac. Med. S. Paulo
56(1):25-35, 2001.
O câncer colorretal (CCR) é a ter-
ceira neoplasia maligna mais freqüen-
te no mundo. No entanto, pouco ou ne-
nhum benefício de sobrevida foi obtido
nos últimos 50 anos. Quanto à doença
genética, crescente investigação
epidemiológica e de genética mole-
cular apontam para a definição de gru-
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